title: Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.
abstract: Background. Androgen deprivation therapy (ADT) in nonmetastatic prostate cancer is unclear. Recent data suggests possible increase in the cardiovascular risks receiving ADT. The aim of the study was to investigate the cardiovascular outcomes in a cohort of Chinese nonmetastatic prostate cancer patients with no previously documented cardiovascular disease. Methods and Results. 745 patients with no previously documented cardiovascular disease and/or diabetes mellitus diagnosed to have nonmetastatic prostate cancer were recruited. Of these, 517 patients received ADT and the remaining 228 did not. After a mean follow-up of 5.3 years, 60 patients developed primary composite endpoint including (1) coronary artery disease, (2) congestive heart failure, and (3) ischemic stroke. Higher proportion of patients on ADT (51 patients, 9.9%) developed composite endpoint compared with those not on ADT (9 patients, 3.9%) with hazard ratio (HR) of 2.06 (95% confidence interval (CI): 1.03-3.24, P = 0.04). Furthermore, Cox regression analysis revealed that only the use of ADT (HR: 2.1, 95% CI: 1.03-4.25, P = 0.04) and hypertension (HR: 2.0, 95% CI: 1.21-3.33, P < 0.01) were independent predictors for primary composite endpoint. Conclusion. ADT in Chinese patients with nonmetastatic prostate cancer with no previously documented cardiovascular disease was associated with subsequent development of cardiovascular events.
authors.affiliation: Division of Cardiology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong ; Cardiology Department, The Second People's Hospital of Chengdu, 610017 Chengdu, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Huang
authors.affiliation: Division of Endocrinology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Chun-Yip
authors.initials: CY
authors.lastname: Yeung
authors.affiliation: Division of Endocrinology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Ka Kui
authors.initials: KK
authors.lastname: Lee
authors.affiliation: Cardiology Department, The Second People's Hospital of Chengdu, 610017 Chengdu, China.
authors.forename: Jianxiong
authors.initials: J
authors.lastname: Liu
authors.affiliation: Division of Urology, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Kwan Lun
authors.initials: KL
authors.lastname: Ho
authors.affiliation: Division of Urology, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Ming-Kwong
authors.initials: MK
authors.lastname: Yiu
authors.affiliation: Division of Endocrinology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Karen Siu-Ling
authors.initials: KS
authors.lastname: Lam
authors.affiliation: Division of Cardiology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Hung-Fat
authors.initials: HF
authors.lastname: Tse
authors.affiliation: Division of Medical Oncology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Thomas
authors.initials: T
authors.lastname: Yau
authors.affiliation: Division of Cardiology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
authors.forename: Chung-Wah
authors.initials: CW
authors.lastname: Siu